Advertisement

Topics

Integrated Approaches for Identifying Molecular Targets in Liver Disease

2019-04-19 12:44:21 | BioPortfolio

Published on BioPortfolio: 2019-04-19T12:44:21-0400

Clinical Trials [1846 Associated Clinical Trials listed on BioPortfolio]

Role of CCL2 in Alcoholic Liver Diseases

Immune dysregulations, including cytokines and chemokines secretions occurs in alcoholic liver disease. Serum levels and liver expression of CCL2 are increased in patients with alcoholic h...

Effect of Non-alcoholic Fatty Liver Disease on Kidney Functions

Non-alcoholic fatty liver disease is the most common cause of chronic liver disease worldwide. It is defined as the accumulation of fat (>5%) in the liver cells in the absence of excessive...

Evaluating Alcohol Use in Alcoholic Liver Disease

This prospective, analytic observational study will investigate alcohol recidivism in patients with alcoholic liver disease. All adult subjects presenting with alcoholic liver disease are ...

Herbal Supplements for Improvement of Liver Function in Participants With Alcoholic Liver Disease

Alcoholic liver disease represents the major health issues and it ranges from simple steatosis to cirrhosis. There is a paucity of data to support the allopathic intervention among these g...

Early Detection of Advanced Fatty Liver Disease

Non-alcoholic fatty liver disease is the most common cause of chronic liver disease in the western world, affecting one in every three subjects. The investigators hypothesize that a patie...

PubMed Articles [18134 Associated PubMed Articles listed on BioPortfolio]

Differing Impact of Sarcopenia and Frailty in Non-Alcoholic Steatohepatitis (NASH) and Alcoholic Liver Disease (ALD).

Sarcopenia and frailty are commonly encountered in patients with end stage liver disease and are associated with adverse clinical outcomes including decompensation and waitlist mortality. The impact o...

Evaluation of metformin therapy using controlled attenuation parameter and transient elastography in patients with non-alcoholic fatty liver disease.

Non-alcoholic fatty liver disease (NAFLD) is among the most common causes of liver disease worldwide. There is growing evidence on pathogenesis and pathophysiology of NAFLD. However, there is still no...

Alcoholic and non-alcoholic fatty liver disease and associations with coronary artery calcification: evidence from the Kangbuk Samsung Health Study.

Recent evidence suggests that alcoholic fatty liver disease (AFLD) and non-alcoholic fatty liver disease (NAFLD) may differentially affect risk of cardiovascular mortality. To investigate whether earl...

Glucocorticosteroids for people with alcoholic hepatitis.

Alcoholic hepatitis is a form of alcoholic liver disease characterised by steatosis, necroinflammation, fibrosis, and complications to the liver. Typically, alcoholic hepatitis presents in people betw...

Yangonin protects against non-alcoholic fatty liver disease through farnesoid X receptor.

Non-alcoholic fatty liver disease (NAFLD) is currently evolving as the most common liver disease worldwide. Dyslipidemia, pathoglycemia and insulin resistance are the major risk factors for the develo...

Medical and Biotech [MESH] Definitions

Liver diseases associated with ALCOHOLISM. It usually refers to the coexistence of two or more subentities, i.e., ALCOHOLIC FATTY LIVER; ALCOHOLIC HEPATITIS; and ALCOHOLIC CIRRHOSIS.

Lipid infiltration of the hepatic parenchymal cells that is due to ALCOHOL ABUSE. The fatty changes in the alcoholic fatty liver may be reversible, depending on the amounts of TRIGLYCERIDES accumulated.

Fatty liver finding without excessive ALCOHOL CONSUMPTION.

Cytoplasmic hyaline inclusions in HEPATOCYTES. They are associated with ALCOHOLIC STEATOHEPATITIS and non-alcoholic STEATOHEPATITIS, but are also present in benign and malignant hepatocellular neoplasms, and metabolic, toxic, and chronic cholestatic LIVER DISEASES.

INFLAMMATION of the LIVER due to ALCOHOL ABUSE. It is characterized by NECROSIS of HEPATOCYTES, infiltration by NEUTROPHILS, and deposit of Mallory hyaline bodies. Depending on its severity, the inflammatory lesion may be reversible or progress to LIVER CIRRHOSIS.

More From BioPortfolio on "Integrated Approaches for Identifying Molecular Targets in Liver Disease"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial